Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8005871 | 0.87 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL7150713 | 0.84 | CA2 (0.33) | CA1CA2CA9 | |
| SCHEMBL21368771 | 0.78 | — | — | |
| SCHEMBL10049628 | 0.78 | — | — | |
| SCHEMBL22073985 | 0.74 | CA2 (0.49) | CA1CA2CA9 | |
| SCHEMBL10018134 | 0.72 | CA1 (0.36) | CA1CA2CA9 | |
| SCHEMBL18610988 | 0.69 | CA2 (0.38) | CA1CA2CA9 | |
| SCHEMBL15084837 | 0.69 | CA2 (0.38) | CA1CA2CA9 | |
| SCHEMBL19185915 | 0.69 | BCHE (0.38) | CA1CA2CA9 | |
| SCHEMBL13365644 | 0.69 | BCHE (0.38) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680078-B2 | Anticancer compounds | GODAVARI BIOREFINERIES LTD. (IN) | 2023-06-20 | — | — | US | disclosed |
| US-8957230-B2 | Synthesis of cleistanthin A and derivatives thereof | GODAVARI BIOREFINERIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| US-20120029179-A1 | PROCESS FOR THE SYNTHESIS OF CLEISTANTHIN | GODAVARI BIOREFINERIES LTD. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680078-B2 | Anticancer compounds | MKI67, CCNI, API5 | CA1 2689/4885CA2 2618/4885CA9 579/4885 |
| US-20120029179-A1 | PROCESS FOR THE SYNTHESIS OF CLEISTANTHIN | SRM, DCXR, CRAT | CA1 546/4885CA2 325/4885CA9 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.